Electric Field Technology going beyond bioprinting to establish next generation applications in regenerative medicine, medical devices, & human-machine interfaces.

The company focuses on the 4D biofabrication of realistic human tissues embedded with biosensors, bioelectronics and/or therapeutic agents. They can be used by researchers and developers to create a better understanding of diseases, for the development of new treatments, safety testing and improvement of existing treatments.

It will increase development speed and time to market for important healthcare solutions. For scalability and more standardization in the development we will utilize our proprietary advanced bioprinting platform which is currently under development. .

• Market:

The regenerative medicine industry is a fast-growing market with a CAGR of over 25% and is estimated to reach $116B in 2026.

Currently animal models are still widely used for this purpose. There has been clear statement from both US and EU on making 2035 the target year to disband all animal trials. At the moment there are limited solutions available to replace or reduce $16B animal trials market.

The new platform will allow the printing of multiple biomaterials in any composition in gradient to create diversity in the 3D tissue. It will utilize advanced tissue engineering technologies as 3D Bioelectrospraying, Cell Electrospinning, and Electrohydrodynamic Jet Bioprinting. These “electric field” technologies are recognized in many publications for their superiority in keeping cells alive and functional which is essential to make realistic tissue.

The company will be marketing both products as well as services. Pricing of the cyborganic application will be market driven and depending on the complexity of the offered or required cyborganic application.  The Human biomaterials will be a support product line. The initial cyborganics applications will involve the 4D In-Vitro tissue models, but in the long-term vision also include potential therapeutic applications. The services that will be promoted and sold are the development of tailored sensor embedded tissue models.

The largest group of stakeholders within the Regenerative medicine market are hospitals. Besides the academic hospitals being involved in research related to regenerative medicine solutions they are also the biggest user of any new clinical applications in this field. There are approximately 8.000 research centers in the world with each having different specialized departments or research groups. Due to the extraordinary costs of advanced systems, only a few have access to advance technology as far that is now available. Although exact numbers are not known what is known is that since the discovery of 3D cell culturing the number of research publications on this subject has increased exponentially. Other stakeholders involved more in tissue engineering and/or the utilization of the advanced in-vitro models are contract research organizations.

Seed: € 450K

Focus on: 

• Manufacturing ready Prototype, 0-series,
• Sensor embedded In-vitro model: Manufacturing ready Prototyp